Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

100.0%

3 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02064010Phase 2Withdrawn

A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia

Role: lead

NCT02217007Phase 2Withdrawn

A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome

Role: lead

NCT02384369Phase 2Withdrawn

Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder

Role: lead

All 3 trials loaded